These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 33158904

  • 1. Biochemical Persistence of Prostate-Specific Antigen After Robot-Assisted Laparoscopic Radical Prostatectomy: Tumor Localizations Using PSMA PET/CT Imaging.
    Meijer D, Donswijk ML, Bodar YJL, van Leeuwen PJ, Poel HGV, Vogel WV, Nieuwenhuijzen JA, Hendrikse NH, Oprea-Lager DE, Vis AN.
    J Nucl Med; 2021 Jul 01; 62(7):961-967. PubMed ID: 33158904
    [Abstract] [Full Text] [Related]

  • 2. Gallium-68-prostate-specific membrane antigen (68 Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer.
    van Leeuwen PJ, Donswijk M, Nandurkar R, Stricker P, Ho B, Heijmink S, Wit EMK, Tillier C, van Muilenkom E, Nguyen Q, van der Poel HG, Emmett L.
    BJU Int; 2019 Jul 01; 124(1):62-68. PubMed ID: 30074667
    [Abstract] [Full Text] [Related]

  • 3. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer.
    Meijer D, Eppinga WSC, Mohede RM, Vanneste BGL, Meijnen P, Meijer OWM, Daniels LA, van den Bergh RCN, Lont AP, Ettema RH, Oudshoorn FHK, van Leeuwen PJ, van der Poel HG, Donswijk ML, Oprea-Lager DE, Schaake EE, Vis AN.
    Eur Urol Oncol; 2022 Apr 01; 5(2):146-152. PubMed ID: 35074282
    [Abstract] [Full Text] [Related]

  • 4. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep 01; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

  • 5. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
    Schmidt-Hegemann NS, Fendler WP, Buchner A, Stief C, Rogowski P, Niyazi M, Eze C, Li M, Bartenstein P, Belka C, Ganswindt U.
    Radiat Oncol; 2017 Nov 10; 12(1):176. PubMed ID: 29126446
    [Abstract] [Full Text] [Related]

  • 6. Predicting early outcomes in patients with intermediate- and high-risk prostate cancer using prostate-specific membrane antigen positron emission tomography and magnetic resonance imaging.
    Meijer D, van Leeuwen PJ, Donswijk ML, Boellaard TN, Schoots IG, van der Poel HG, Hendrikse HN, Oprea-Lager DE, Vis AN.
    BJU Int; 2022 Jan 10; 129(1):54-62. PubMed ID: 34028165
    [Abstract] [Full Text] [Related]

  • 7. Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection.
    Baas DJH, Schilham M, Hermsen R, de Baaij JMS, Vrijhof HJEJ, Hoekstra RJ, Sedelaar JPM, Küsters-Vandevelde HVN, Gotthardt M, Wijers CHW, van Basten JP, Somford DM.
    Prostate Cancer Prostatic Dis; 2022 Mar 10; 25(1):65-70. PubMed ID: 34471231
    [Abstract] [Full Text] [Related]

  • 8. Prognostic significance of a negative PSMA PET/CT in biochemical recurrence of prostate cancer.
    Harsini S, Martineau P, Plaha S, Saprunoff H, Chen C, Bishop J, Tyldesley S, Wilson D, Bénard F.
    Cancer Imaging; 2024 Aug 30; 24(1):117. PubMed ID: 39210431
    [Abstract] [Full Text] [Related]

  • 9. Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy.
    Schmidt-Hegemann NS, Fendler WP, Ilhan H, Herlemann A, Buchner A, Stief C, Eze C, Rogowski P, Li M, Bartenstein P, Ganswindt U, Belka C.
    Radiat Oncol; 2018 Mar 02; 13(1):37. PubMed ID: 29499730
    [Abstract] [Full Text] [Related]

  • 10. Ga68-PSMA PET for lymph node staging in intermediate and high-risk prostate cancer patients undergoing robotic assisted radical prostatectomy.
    Spena G, Moretti TB, Dávila FS, Dos Anjos G, Khan I, Calace FP, Aveta A, Pandolfo SD, Tufano A, Izzo A, Farias A, Perdonà S, Maes K.
    Minerva Urol Nephrol; 2024 Aug 02; 76(4):467-473. PubMed ID: 39051893
    [Abstract] [Full Text] [Related]

  • 11. 18F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy.
    Mena E, Lindenberg ML, Turkbey IB, Shih JH, Harmon SA, Lim I, Lin F, Adler S, Eclarinal P, McKinney YL, Citrin D, Dahut W, Wood BJ, Krishnasamy V, Chang R, Levy E, Merino M, Pinto P, Eary JF, Choyke PL.
    J Nucl Med; 2020 Jun 02; 61(6):881-889. PubMed ID: 31676732
    [Abstract] [Full Text] [Related]

  • 12. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.
    Rauscher I, Düwel C, Haller B, Rischpler C, Heck MM, Gschwend JE, Schwaiger M, Maurer T, Eiber M.
    Eur Urol; 2018 May 02; 73(5):656-661. PubMed ID: 29358059
    [Abstract] [Full Text] [Related]

  • 13. Treatment Outcomes from 68Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET.
    Emmett L, van Leeuwen PJ, Nandurkar R, Scheltema MJ, Cusick T, Hruby G, Kneebone A, Eade T, Fogarty G, Jagavkar R, Nguyen Q, Ho B, Joshua AM, Stricker P.
    J Nucl Med; 2017 Dec 02; 58(12):1972-1976. PubMed ID: 28747524
    [Abstract] [Full Text] [Related]

  • 14. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].
    Veliev EI, Tomilov AA, Goncharuk DA, Bogdanov AB, Golubtsova EN.
    Urologiia; 2018 Jul 02; (3):105-110. PubMed ID: 30035428
    [Abstract] [Full Text] [Related]

  • 15. Prospective evaluation of 68Ga-PSMA-11 PET/CT in Chinese men with biochemical recurrence after radical prostatectomy for prostate cancer: relationships between location of recurrence, time after prostatectomy, and serum PSA level.
    Dong L, Zhu Y, Xin M, Dong B, Pan J, Liu J, Amend SR, Xue W, Pienta KJ, Rowe SP.
    Med Oncol; 2020 Sep 12; 37(10):89. PubMed ID: 32920666
    [Abstract] [Full Text] [Related]

  • 16. Patterns of relapse as determined by 68Ga-PSMA ligand PET/CT after radical prostatectomy : Importance for tailoring and individualizing treatment.
    Henkenberens C, Derlin T, Bengel FM, Ross TL, Wester HJ, Hueper K, Kuczyk MA, Christiansen H, von Klot CA.
    Strahlenther Onkol; 2018 Apr 12; 194(4):303-310. PubMed ID: 29134231
    [Abstract] [Full Text] [Related]

  • 17. A pictorial view on false positive findings of 68Ga-PSMA-11 PET/CT and their prognostic value in patients with prostate carcinoma after radical prostatectomy and undetectable PSA values.
    Dancheva Z, Chausheva S, Stoeva T, Dyankova M, Yordanova T, Chaushev B, Marinov R, Nikolov V, Abushev P, Todorov G, Dimitrova E, Klisarova A, Anakievski D.
    Hell J Nucl Med; 2024 Apr 12; 27(1):16-26. PubMed ID: 38629815
    [Abstract] [Full Text] [Related]

  • 18. Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial.
    Bodar YJL, Jansen BHE, van der Voorn JP, Zwezerijnen GJC, Meijer D, Nieuwenhuijzen JA, Boellaard R, Hendrikse NH, Hoekstra OS, van Moorselaar RJA, Oprea-Lager DE, Vis AN.
    World J Urol; 2021 Jul 12; 39(7):2439-2446. PubMed ID: 33079250
    [Abstract] [Full Text] [Related]

  • 19. Primary lymph-node staging with 68Ga-PSMA PET in high-risk prostate cancer: pathologic correlation with extended pelvic lymphadenectomy specimens.
    Corona-Montes VE, González-Cuenca E, Fernández-Noyola G, Olarte-Casas MA, Bobadilla-Salazar D, Medrano-Urtecho HM, Asimakopoulos AD.
    Urol Oncol; 2021 Aug 12; 39(8):494.e1-494.e6. PubMed ID: 33223371
    [Abstract] [Full Text] [Related]

  • 20. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
    Rogowski P, Trapp C, von Bestenbostel R, Eze C, Ganswindt U, Li M, Unterrainer M, Zacherl MJ, Ilhan H, Beyer L, Kretschmer A, Bartenstein P, Stief C, Belka C, Schmidt-Hegemann NS.
    Eur J Nucl Med Mol Imaging; 2022 Mar 12; 49(4):1417-1428. PubMed ID: 34628521
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.